Inactive Instrument

Press Releases Diamyd Medical AB (publ) Nasdaq Stockholm

Equities

SE0005162880

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Diamyd Medical announces final outcome in the company's rights issue	Apr. 18	AQ
Diamyd Medical announces preliminary outcome in the company's rights issue	Apr. 16	AQ
Recruitment milestone reached in Diamyd® Phase 3 trial	Apr. 12	AQ
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes	Apr. 11	AQ
Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue	Apr. 05	AQ
Diamyd Medical publishes prospectus with regards to the rights issue	Mar. 28	AQ
Quarterly Report II 23/24	Mar. 27	AQ
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million	Mar. 18	AQ
Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA	Feb. 29	AQ
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®	Feb. 15	AQ
Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening	Feb. 14	AQ
In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion	Jan. 24	AQ
Quarterly Report I 23/24	Jan. 24	AQ
Diamyd Medical gains market research findings to guide U.S. commercial strategy	Jan. 08	AQ
Diamyd® precision medicine Phase 3 trial key interim analysis in July	Jan. 04	AQ
Diamyd Medical's Precision Medicine patent for the prevention and treatment of autoimmune diabetes granted in South Korea	Dec. 06	AQ
Bulletin from Annual General Meeting of Diamyd Medical AB	Nov. 30	AQ
Annual Report 2022/2023	Nov. 29	AQ
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	Nov. 09	AQ
Information about the Annual Report 2022/23	Nov. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Diamyd Medical AB (publ) Nasdaq Stockholm

Equities

SE0005162880

Press Releases

Filters